Key result
Chronic administration of trimetazidine had no significant effect on long-term mortality (17% vs 16%, P=0.8) or left ventricular ejection fraction (35% vs 36%, P=0.6) in a rat model of MI.
Why the study?
Does trimetazidine improve left ventricular function and survival after myocardial infarction and reperfusion in a rat model?
Population
200 male Wistar rats subjected to myocardial infarction (MI) and reperfusion or sham surgery
Comparison
Trimetazidine diet administered chronically pre-MI vs Control diet
Design
Preclinical
Follow-up
24 weeks
Authors
Loading...
Trimetazidine shows no post-MI benefit in rats; leaves open any role in human ischemia-reperfusion injury.
Does trimetazidine improve left ventricular function and survival after myocardial infarction and reperfusion in a rat model?
Absolute Event Rate: 17% vs 16%
p-value: p=0.8
Chronic pre-MI administration of trimetazidine did not improve post-MI left ventricular dysfunction, remodeling, or survival in a rat model of ischemia-reperfusion.
Mouquet et al. (2010) studied Myocardial infarction (n=200). Trimetazidine vs. Control diet was evaluated on Long-term mortality over 24 weeks (p=0.8). Chronic administration of trimetazidine had no significant effect on long-term mortality (17% vs 16%, P=0.8) or left ventricular ejection fraction (35% vs 36%, P=0.6) in a rat model of MI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: